Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invitae Corp (NY: NVTA )

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Feb 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 0.0888 (12)
Ask (Size) 0.0896 (75)
Prev. Close 0.0891
Today's Range N/A - N/A
52wk Range 0.3601 - 0.7639
Shares Outstanding 217,339,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sales growth. The acquisition of Invitae is expected to bolster Labcorp's... 
Via Benzinga
Softbank-Backed Cohesity To Acquire Veritas Data Security Unit For $3B: Report
Cohesity, a U.S.-based data security software company, is set to acquire the data protection business of Veritas, a subsidiary of Carlyle Group. 
Via Benzinga

Performance

More News

Read More
US Stocks Gain; Uber Posts Upbeat Sales
Via Benzinga
Topics Stocks
Exposures US Equities
The New York Stock Exchange Will Start Delisting Invitae (NVTA) Stock
Via InvestorPlace
Why Is Agrify (AGFY) Stock Up 57% Today?
Via InvestorPlace
Is Invitae Stock a Buy Now?
Via The Motley Fool
Looking Into Invitae's Recent Short Interest
Via Benzinga
(NVTA) - Analyzing Invitae's Short Interest
Via Benzinga
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Why Is Invitae (NVTA) Stock Down 75% Today?
Via InvestorPlace
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Invitae’s High-Stakes Financial Maneuvering: Dilution Might Not Be That Bad
Via Talk Markets
Earnings Preview: Invitae
Via Benzinga
Is Invitae Stock a Buy Now?
Via The Motley Fool
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit
Via Benzinga
Invitae Layoffs 2023: What to Know About the Latest NVTA Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Better Growth Stock: CRISPR Therapeutics vs. Invitae
Via The Motley Fool
Invitae (NVTA) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
3 Things About Invitae Every Smart Investor Knows
Via The Motley Fool
3 Penny Stocks That Look Like Intriguing Bets for the Long-Term
Via InvestorPlace
Why Invitae Stock Popped Today
Via The Motley Fool
Exposures Product Safety
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.